We are monitoring the impact of COVID-19 on APAC Ovarian Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1394
Share on
Share on

Asia-Pacific Ovarian Cancer Therapeutics Market Research Report – Segmented By Stage Of Cancer, Cancer Type, Diagnosis, Type Of Treatment & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1394
Pages: 181

APAC Ovarian Cancer Therapeutics Market Size (2021 to 2026)

The size of the Asia Pacific Ovarian Cancer Therapeutics Market is estimated to be growing at a healthy CAGR from 2021 to 2026.

The ovarian cancer therapeutics market in APAC is expected to be led by the proliferation of new ovarian cancer cases, growing demand for effective treatment, and increasing healthcare expenditure. Also, the rising burden of ovarian cancer and technological advancements are expected to uplift the market. China and India are regarded as two of the most promising countries in the world, with huge market potential. Rising ovarian cancer incidence, positive medical care reforms, growing health awareness, a low-cost base, and a lack of legal and cultural barriers contribute to the market's growth in India and China. In addition, companies are reorganizing their operations and recovering from the impact of COVID-19, which had previously resulted in restrictive containment measures like social distancing, remote working, and the closure of commercial activities, all of which created operational challenges, are driving market growth in APAC.

Every year, more than 6 million new cancer cases are identified in Asia, according to the World Health Organization (WHO). Cancer is the main cause of mortality, and the rate of occurrence is growing every year. As a result, the demand for high-quality cancer therapies has skyrocketed, propelling the market forward. According to the Hong Kong Department of Health, ovarian cancer is the sixth most frequent disease among women in Hong Kong, with 563 new cases identified in 2014. The prevalence is anticipated to grow in the future years. As a result, the Asia-Pacific ovarian cancer diagnostics and treatments market is growing at a rapid pace.

The lack of trained experts, on the other hand, is posing a challenge to the market's expansion. In addition, the ovarian cancer treatments industry's expansion is being hampered by a shortage of financing for research and development efforts. Furthermore, the lack of sufficient technology for identifying ovarian cancer in its early stages is a key barrier impeding the worldwide ovarian cancer therapeutics market growth.

This research report on the APAC ovarian cancer therapeutics market has been segmented and sub-segmented into the following categories:

By Stage of Cancer:

  • Stage I
    • Stage IA
    • Stage IB
    • Stage IC
  • Stage II
    • Stage IIA
    • Stage IIB
    • Stage IIC
  • Stage III
    • Stage IIIA
    • Stage IIIB
    • Stage IIIC
  • Stage IV

By Cancer Type:

  • Primary Peritoneal Carcinoma
  • Ovarian Stromal Tumors
  • Ovarian Germ Cell Tumors
  • Epithelial Ovarian Tumors

By Diagnosis:

  • Physical Examination
  • Blood Tests
  • Ultrasound
  • PET
  • CT Scan
  • MRI
  • Human Chorionic Gonadotropin Test
  • Biopsy

By Type of Treatment:

  • Chemotherapy
  • Radiation Therapy
  • Hormonal Therapy
  • Surgery
  • Immunotherapy
  • Targeted Therapy

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the APAC Ovarian Cancer Therapeutics Market is anticipated to witness a significant share during the forecast period. The regional market growth is driven by the rising incidence of ovarian cancer, the demand for quality cancer treatments dramatically, and technological advancements in the healthcare sector. In addition, cancer is the leading cause of mortality, and the rate of occurrence is growing every year. As a result, the demand for high-quality cancer therapies has grown substantially, adding to the APAC market expansion. However, Pharmaceutical companies in the ovarian cancer drugs market invest in the research and development of innovative products; the presence of emerging countries such as China, Japan, and India are majorly contributing to the regional market growth.

KEY MARKET PLAYERS:

Some of the major players in this market are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Genentech Inc.  

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Stage Of Cancer                        

                                5.1.1 Stage I       

                                                5.1.1.1 Stage IA

                                                5.1.1.2 Stage IB

                                                5.1.1.3 Stage IC

                                5.1.2 Stage II     

                                                5.1.2.1 Stage IIA

                                                5.1.2.2 Stage IIB

                                                5.1.2.3 Stage IIC

                                5.1.3 Stage III    

                                                5.1.3.1 Stage IIIA

                                                5.1.3.2 Stage IIIB

                                                5.1.3.3 Stage IIIC

                                5.1.4 Stage IV    

                                5.1.5 Y-o-Y Growth Analysis, By Stage Of Cancer

                                5.1.6 Market Attractiveness Analysis, By Stage Of Cancer               

                                5.1.7 Market Share Analysis, By Stage Of Cancer

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 Primary Peritoneal Carcinoma        

                                5.2.3 Ovarian Stromal Tumors   

                                5.2.4 Ovarian Germ Cell Tumors

                                5.2.5 Epithelial Ovarian Tumors

                                5.2.6 Y-o-Y Growth Analysis, By Type      

                                5.2.7 Market Attractiveness Analysis, By Type     

                                5.2.8 Market Share Analysis, By Type      

                5.3 Diagnosis                     

                                5.3.1 Introduction           

                                5.3.2 Physical Examination          

                                5.3.3 Blood Tests             

                                5.3.4 Ultrasound             

                                5.3.5 PET             

                                5.3.6 CT Scan     

                                5.3.7 MRI            

                                5.3.8 Human Chorionic Gonadotropin Test          

                                5.3.9 Biopsy       

                                5.3.10 Y-o-Y Growth Analysis, By Diagnosis          

                                5.3.11 Market Attractiveness Analysis, By Diagnosis         

                                5.3.12 Market Share Analysis, By Diagnosis          

                5.4 Treatment                  

                                5.4.1 Introduction           

                                5.4.2 Chemotherapy     

                                5.4.3 Radiation Therapy

                                5.4.4 Hormonal Therapy              

                                5.4.5 Surgery    

                                5.4.6 Immunotherapy   

                                5.4.7 Targeted Therapy

                                5.4.8 Y-o-Y Growth Analysis, By Treatment          

                                5.4.9 Market Attractiveness Analysis, By Treatment         

                                5.4.10 Market Share Analysis, By Treatment       

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Aetera Zenteris Inc.                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Eli Lilly and Company                             

                8.3 Roche                           

                8.4 Amgen                         

                8.5 Janssen Pharmaceuticals, Inc.                             

                8.6 Bristol Myers Squibb Company                          

                8.7 Novogen, Inc.                            

                8.8 GlaxoSmithKline                      

                8.9 Boehringer Ingelheim                            

                8.10 AstraZeneca                            

                8.11 Genentech Inc.                       

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  2. Asia-Pacific Stage I Market, By Region, From 2021 to 2026 (USD Billion)
  3. Asia-Pacific Stage II Market, By Region, From 2021 to 2026 (USD Billion)
  4. Asia-Pacific Stage III Market, By Region, From 2021 to 2026 (USD Billion)
  5. Asia-Pacific Stage IV Market, By Region, From 2021 to 2026 (USD Billion)
  6. Asia-Pacific Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  7. Asia-Pacific Primary Peritoneal Carcinoma Market, By Region, From 2021 to 2026 (USD Billion)
  8. Asia-Pacific Ovarian Stromal Tumors Market, By Region, From 2021 to 2026 (USD Billion)
  9. Asia-Pacific Ovarian Germ Cell Tumors Market, By Region, From 2021 to 2026 (USD Billion)
  10. Asia-Pacific Epithelial Ovarian Tumors Market, By Region, From 2021 to 2026 (USD Billion)
  11. Asia-Pacific Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  12. Asia-Pacific Physical Examination Market, By Region, From 2021 to 2026 (USD Billion)
  13. Asia-Pacific Blood Tests Market, By Region, From 2021 to 2026 (USD Billion)
  14. Asia-Pacific Ultrasound Market, By Region, From 2021 to 2026 (USD Billion)
  15. Asia-Pacific PET Market, By Region, From 2021 to 2026 (USD Billion)
  16. Asia-Pacific CT Scan Market, By Region, From 2021 to 2026 (USD Billion)
  17. Asia-Pacific MRI Market, By Region, From 2021 to 2026 (USD Billion)
  18. Asia-Pacific Human Chorionic Gonadotropin Test Market, By Region, From 2021 to 2026 (USD Billion)
  19. Asia-Pacific Biopsy Market, By Region, From 2021 to 2026 (USD Billion)
  20. Asia-Pacific Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  21. Asia-Pacific Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  22. Asia-Pacific Radiation Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  23. Asia-Pacific Hormonal Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  24. Asia-Pacific Surgery Market, By Region, From 2021 to 2026 (USD Billion)
  25. Asia-Pacific Immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  26. Asia-Pacific Targeted Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  27. Japan Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  28. Japan Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  29. Japan Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  30. Japan Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  31. China Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  32. China Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  33. China Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  34. China Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  35. India Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  36. India Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  37. India Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  38. India Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  39. Australia Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  40. Australia Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  41. Australia Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  42. Australia Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  43. South Korea Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  44. South Korea Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  45. South Korea Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  46. South Korea Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  47. Asia-Pacific Blood Glucose Monitoring Market, By Stage I, From 2021 to 2026 (USD Billion)
  48. Asia-Pacific Stage IA Market, By Region, From 2021 to 2026 (USD Billion)
  49. Asia-Pacific Stage IB Market, By Region, From 2021 to 2026 (USD Billion)
  50. Asia-Pacific Stage IC Market, By Region, From 2021 to 2026 (USD Billion)
  51. Japan Blood Glucose Monitoring Market, By Stage I, From 2021 to 2026 (USD Billion)
  52. China Blood Glucose Monitoring Market, By Stage I, From 2021 to 2026 (USD Billion)
  53. India Blood Glucose Monitoring Market, By Stage I, From 2021 to 2026 (USD Billion)
  54. Australia Blood Glucose Monitoring Market, By Stage I, From 2021 to 2026 (USD Billion)
  55. Asia-Pacific Blood Glucose Monitoring Market, By Stage II, From 2021 to 2026 (USD Billion)
  56. Asia-Pacific Stage IIA Market, By Region, From 2021 to 2026 (USD Billion)
  57. Asia-Pacific Stage IIB Market, By Region, From 2021 to 2026 (USD Billion)
  58. Asia-Pacific Stage IIC Market, By Region, From 2021 to 2026 (USD Billion)
  59. Japan Blood Glucose Monitoring Market, By Stage II, From 2021 to 2026 (USD Billion)
  60. China Blood Glucose Monitoring Market, By Stage II, From 2021 to 2026 (USD Billion)
  61. India Blood Glucose Monitoring Market, By Stage II, From 2021 to 2026 (USD Billion)
  62. Australia Blood Glucose Monitoring Market, By Stage II, From 2021 to 2026 (USD Billion)
  63. Asia-Pacific Blood Glucose Monitoring Market, By Stage III, From 2021 to 2026 (USD Billion)
  64. Asia-Pacific Stage IIIA Market, By Region, From 2021 to 2026 (USD Billion)
  65. Asia-Pacific Stage IIIB Market, By Region, From 2021 to 2026 (USD Billion)
  66. Asia-Pacific Stage IIIC Market, By Region, From 2021 to 2026 (USD Billion)
  67. Japan Blood Glucose Monitoring Market, By Stage III, From 2021 to 2026 (USD Billion)
  68. China Blood Glucose Monitoring Market, By Stage III, From 2021 to 2026 (USD Billion)
  69. India Blood Glucose Monitoring Market, By Stage III, From 2021 to 2026 (USD Billion)
  70. Australia Blood Glucose Monitoring Market, By Stage III, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample